PBYI Q2 2018 Earnings — Puma Biotechnology, Inc. Revenue & Financial Results | Market Cap Arena

PBYIPuma Biotechnology, Inc.

$299M

Q2 2018 Earnings

Healthcare Biotechnology

Income Statement

Revenue

$51M

Gross Profit

$42M82.6% margin

Operating Income

-$41M-81.6% margin

Net Income

-$44M-87.3% margin

EPS (Diluted)

$-1.17

QoQ Revenue Growth

-23.7%

Cash Flow

Operating Cash Flow

-$18M

Free Cash Flow

-$18M

Stock-Based Comp.

$22M

Balance Sheet

Total Assets

$228M

Total Liabilities

$189M

Stockholders' Equity

$38M

Cash & Equivalents

$96M

Year-over-Year Comparison

Metric	Current	Year Ago	Change
Revenue	$51M	$0	—
Gross Profit	$42M	$0	—
Operating Income	-$41M	-$78M	+47.0%
Net Income	-$44M	-$78M	+43.0%

Revenue Segments

Product

$51M62%

License

$31M38%